You can reach Jason on Signal at JasonMast.05. Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic ...

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that missed analysts’ expectations and disclosed narrower-than-expected access ...

A Vertex Pharmaceuticals therapeutic candidate designed to avoid immunosuppression has fallen short of its efficacy goals in a clinical trial, leading the drugmaker to discontinue the program.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex Pharmaceuticals will stay at its prominent headquarters on Fan Pier in Boston’s Seaport District after considering moving to another spot in the neighborhood, according to three real ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...